Healthcare Jul 07, 2021 10:29 AM (GMT+8)
Euro health learned on the 7th that recently, Nahua Biotechnology (Changzhou) Co., Ltd. (hereinafter referred to as "Nahua biology") has completed tens of millions of yuan of a + round financing. This round of financing is jointly invested by Shenzhen Venture Capital and Xinghe capital. The funds will be mainly used for the development, promotion and sales of the existing sports medicine, dental consumables and minimally invasive surgery consumables products of Nahua biology.
Founded in 2013, novabio focuses on high growth minimally invasive surgery (minimally invasive surgery, sports medicine) and Medical Cosmetology (oral, skin / wound). At present, based on its two global original and leading platform technologies - "nanofiber reinforced composites" and "low temperature plasma", novabio has developed sports medicine and dental products, as well as innovative products applied in dental, wound care and other fields. It is reported that the R & D of these two core platform technologies began more than 10 years ago, and has been supported by NIH (National Institutes of Health) and NSF (National Science Foundation) of the United States federal government (with a total count of millions of dollars).
Up to now, Nawa bio has 8 FDA 510 (k) products, and has obtained the first class II medical device registration certificate in China, and a number of products are in the application process. In addition, its products have begun to sell in North America, Latin America and the Middle East, with steady and rapid growth in sales and layout in the domestic market.
This text is a result of machine translation.